4-octadecyloxypyridine | 1321654-95-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-octadecyloxypyridine
• 英文别名: 4-Octadecoxypyridine
• CAS: 1321654-95-8
• 化学式: C₂₃H₄₁NO
• 分子量: 347.585
• InChiKey: ZSWINMZBGNYCPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.7
• 重原子数：
  25
• 可旋转键数：
  18
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-octadecyloxypyridine 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 40.0h， 以98%的产率得到4-octadecyloxypyridinium chloride
  参考文献：
  名称：

  4-羟基吡啶衍生的离子液晶

  摘要：

  取决于烷基化的位点（N 或 O），4-羟基吡啶的单烷基化产生中性 N-烷基-4-吡啶酮或 4-烷氧基吡啶。这两种中性化合物的进一步烷基化产生了具有两条长烷基链的 N-烷基-4-烷氧基溴化吡啶的离子液晶 (ILC)。或者，两种中性化合物与 HCl 的简单质子化也诱导形成 N-烷基-4-羟基吡啶鎓氯化物或 4-烷氧基吡啶鎓盐酸盐的 ILC。通过单晶 X 射线衍射确定了两种不同类型的离子液晶和一种中性化合物的晶体结构。通过差示扫描量热法、偏光显微镜和粉末 X 射线衍射法检查中间相性质。阴离子影响二烷基化化合物中中间相的结构和稳定性。利用核磁共振扩散级谱技术研究了一些典型化合物在溶液中的自组装行为。最后，制备并表征了由吡啶鎓盐稳定的稳定的金纳米颗粒。

  DOI：

  10.1039/c0sm01376e
• 作为产物：
  描述：

  硬脂醇 、 4-氯吡啶盐酸盐 在 sodium hydroxide 作用下， 以 二甲基亚砜 为溶剂， 反应 0.5h， 生成 4-octadecyloxypyridine
  参考文献：
  名称：

  4-烷氧基吡啶作为两性离子液晶中间体的合成

  摘要：

  在粉末 NaOH 存在下，通过 4-氯吡啶盐酸盐与适当的醇在 DMSO 中反应，以 75-80% 的典型收率获得了一系列 n = 5-18 的 4-烷氧基吡啶。将报告的合成与其他制备 4-烷氧基吡啶的方法进行比较，并对其用途进行了审查。4-十三烷氧基吡啶转化为 [closo-B10H10] 的双两性离子衍生物，呈现液晶相和软结晶相。通过单晶XRD方法建立了两种吡啶和双两性离子的固态结构。研究了 N 原子配位对吡啶环几何形状的影响。

  DOI：

  10.24820/ark.5550190.p010.700

文献信息

• Gemini pyridinium amphiphiles for the synthesis and stabilization of gold nanoparticles for drug delivery
  作者：María E. Alea-Reyes、Asensio González、Ana C. Calpena、David Ramos-López、Joaquín de Lapuente、Lluïsa Pérez-García

  DOI：10.1016/j.jcis.2017.04.064

  日期：2017.9

  play a triple role as: gold nanoparticles (AuNPs) synthesis facilitator, particle stabilizer and anion recognition centre. The so formed nanoparticles should be able to bind and release anionic drugs. EXPERIMENTS We describe (a) Synthesis, by a phase transfer method, of both new organic media and water soluble AuNPs using gemini-type surfactants based on bis-pyridinium salts as ligands, acting as transfer

  假设双子座基于吡啶鎓的两亲物可以发挥三重作用：金纳米颗粒（AuNPs）合成促进剂，颗粒稳定剂和阴离子识别中心。如此形成的纳米颗粒应能够结合并释放阴离子药物。实验我们描述了（a）使用双吡啶盐基双子型表面活性剂作为配体，通过相转移方法合成新的有机介质和水溶性AuNP，既作为转移剂进入有机介质，又作为纳米稳定剂， （b）检查其在溶液中的稳定性，（c）纳米颗粒的化学和物理特征，（d）有关双吡啶配体和双吡啶包覆的纳米颗粒的毒性数据，以及（e）研究它们的能力提供阴离子药物，例如布洛芬和吡罗昔康。研究结果吡啶双晶型表面活性剂显示出发挥多种作用的能力，例如转移剂，稳定剂以及离子载体：它们负责这些AuNP的制备，稳定性和传递性质，其中金核被存在的阴离子所稳定在双吡啶盐中。由于双吡啶盐的自发氧化成相应的吡啶鎓盐，所以由双吡啶盐的还原产生的四氢吡啶能够还原金，从而形成稳定的AuNPs。
• PROCESS FOR PRODUCING OXYGENIC COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1797953A1

  公开（公告）日：2007-06-20

  An oxidation catalyst composition is obtained by mixing a selenium compound, a nitrogen-containing aromatic compound and an acid, and if necessary, in the presence of a solvent. The oxidation catalyst composition shows an oxidation catalyst activity in the oxidation reaction of an organic compound. For example, at least one oxygen-containing compound selected from an alcohol compound, an aldehyde compound, a ketone compound and a carboxylic acid compound is obtained by reacting the olefin compound having two or more hydrogen atoms on the carbon atom at α-position of a carbon-carbon double bond with an organic hydroperoxide compound in the presence of the oxidation catalyst composition.

  将硒化合物、含氮芳香族化合物和酸混合，必要时在有溶剂存在的情况下，可得到一种氧化催化剂组合物。氧化催化剂组合物在有机化合物的氧化反应中显示出氧化催化剂活性。例如，将碳碳双键 α 位碳原子上有两个或两个以上氢原子的烯烃化合物与有机过氧化氢化合物在氧化催化剂组合物存在下进行反应，可获得至少一种选自醇化合物、醛化合物、酮化合物和羧酸化合物的含氧化合物。
• Highly quadrupolar derivatives of the [closo-B10H10]2- anion: Investigation of liquid crystalline polymorphism in an homologous series of 1,10-bis(4-alkoxypyridinium) zwitterions
  作者：Muhammad O. Ali、Damian Pociecha、Jakub Wojciechowski、Irina Novozhilova、Andrienne C. Friedli、Piotr Kaszyński

  DOI：10.1016/j.jorganchem.2018.04.003

  日期：2018.6

  A series of pyridinium bis-zwitterions [closo-B10H8-1,10-2 (4-ROC5H4N)] (1[u]) was obtained in 55-60% yield by reacting [closo-B10H8-1,10-2(1Ph)] (3) with 4-alkoxypyridines and the resulting derivatives were analyzed for their liquid crystalline properties. Optical, thermal and XRD analyses revealed the formation of a nematic and rare lamellar phases, Lama, driven by dipolar interactions. Upon elongation of the terminal alkoxy chain, the nematic phase is gradually replaced by the lamellar polymorphism. The solidstate structures of 1[8], 1[12] and 1[16] were established by single crystal XRD:1[12] p-1,z=2,a= 9.6262 (2) angstrom,b = 12.0464(2) angstrom, c=12.611150(10) angstrom,beta=103.9910(10)degrees;1[12] p-1,Z=2,a=9.6262,(2) angstrom,b = 12.0464(2) angstrom, c=17.9226(3)angstrom, alpha=80.5940(10)degrees, beta= 83.0700(10)degrees, gamma=74.9860(10)degrees; 1[16] p-1, Z=2,a=9.6827 (3) angstrom,b = 11.6711 (5) angstrom, c= 22.8486(7) angstrom, alpha=77.416(3)degrees, beta = 86.925(2)degrees,gamma=66.202 (4)Alpha degrees
• Method for Producing Oxygen-Containing Compound
  申请人：Hagiya Koji

  公开号：US20080064898A1

  公开（公告）日：2008-03-13

  An oxidation catalyst composition is obtained by mixing a selenium compound, a nitrogen-containing aromatic compound and an acid, and if necessary, in the presence of a solvent. The oxidation catalyst composition shows an oxidation catalyst activity in the oxidation reaction of an organic compound. For example, at least one oxygen-containing compound selected from an alcohol compound, an aldehyde compound, a ketone compound and a carboxylic acid compound is obtained by reacting the olefin compound having two or more hydrogen atoms on the carbon atom at α-position of a carbon-carbon double bond with an organic hydroperoxide compound in the presence of the oxidation catalyst composition.
• Synthesis and Validation of TRIFAPYs as a Family of Transfection Agents for Therapeutic Oligonucleotides
  作者：Berta Isanta、Ana Delgado、Carlos J. Ciudad、Mª Antònia Busquets、Rosa Griera、Núria Llor、Véronique Noé

  DOI：10.3390/biom14040390

  日期：——

  Transfection agents play a crucial role in facilitating the uptake of nucleic acids into eukaryotic cells offering potential therapeutic solutions for genetic disorders. However, progress in this field needs the development of improved systems that guarantee efficient transfection. Here, we describe the synthesis of a set of chemical delivery agents (TRIFAPYs) containing alkyl chains of different lengths based on the 1,3,5-tris[(4-alkyloxy-1pyridinio)methyl]benzene tribromide structure. Their delivery properties for therapeutic oligonucleotides were evaluated using PolyPurine Reverse Hoogsteen hairpins (PPRHs) as a silencing tool. The binding of liposomes to PPRHs was evaluated by retardation assays in agarose gels. The complexes had a size of 125 nm as determined by DLS, forming well-defined concentrical vesicles as visualized by Cryo-TEM. The prostate cancer cell line PC-3 was used to study the internalization of the nanoparticles by fluorescence microscopy and flow cytometry. The mechanism of entrance involved in the cellular uptake was mainly by clathrin-mediated endocytosis. Cytotoxicity analyses determined the intrinsic toxicity caused by each TRIFAPY and the effect on cell viability upon transfection of a specific PPRH (HpsPr-C) directed against the antiapoptotic target survivin. TRIFAPYs C12-C18 were selected to expand these studies in the breast cancer cell line SKBR-3 opening the usage of TRIFAPYs for both sexes and, in the hCMEC/D3 cell line, as a model for the blood–brain barrier. The mRNA levels of survivin decreased, while apoptosis levels increased upon the transfection of HpsPr-C with these TRIFAPYs in PC-3 cells. Therefore, TRIFAPYs can be considered novel lipid-based vehicles for the delivery of therapeutic oligonucleotides.